Medindia

X

WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development

Monday, January 11, 2010 Corporate News J E 4
Advertisement
SHANGHAI, Jan. 10 WuXi AppTec Inc. today announcedthat it has entered into a partnership with QIAGEN to provide an integratedsingle solution for molecular biomarker development, validation andpersonalized healthcare targets to their respective client bases. QIAGEN willprovide a complete portfolio of instrumentation, training, and consumables andWuXi AppTec will provide laboratory facilities and staff to execute theservices. The laboratory will be located at WuXi AppTec's campus in Shanghaiand will begin operating immediately.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Under the terms of the partnership agreement, WuXi AppTec will also workwith QIAGEN to help develop biomarkers, assay panels, personalized healthcarediagnostics, and other products that QIAGEN intends to bring to market. WuXiAppTec will use QIAGEN's technologies for a broad range of applications insupport of drug discovery and development on behalf of the company's andQIAGEN's customers. WuXi AppTec and QIAGEN will also co-promote each other'sservices to their respective customers. Both companies are working closely toidentify additional opportunities to deepen their relationship.

"WuXi AppTec has long been interested in partnering with a premierinternational molecular biotechnology company like QIAGEN to support thedevelopment of our biomarker business," said Dr. Ge Li, Chairman and CEO ofWuXi AppTec. "This partnership gives us access to innovative technologies andprocesses that will allow us to better serve our customers."

"We are very pleased to have entered into this partnership with WuXiAppTec, a global leader in providing integrated research and developmentservices to the pharmaceutical industry," said Dr. Victor Shi, President,Asia Pacific of QIAGEN. "In doing so, we have created what we believe to bethe first laboratory of its kind in Asia equipped with a standardized, fullyintegrated, automated sample and assay technology platform for drug discoveryand development and molecular diagnostics in personalized healthcare and otherareas. We believe that this partnership is a significant milestone inproviding high-quality and complete automated solutions for the molecularbiomarker testing industry."

About WuXi AppTec:

WuXi AppTec is a leading pharmaceutical, biotechnology, and medical-deviceR&D outsourcing company, with operations in China and the United States. As aresearch-driven and customer-focused company, WuXi AppTec provides a broad andintegrated portfolio of laboratory and manufacturing services throughout thepharmaceutical and medical-device R&D process. WuXi AppTec's services aredesigned to help its global partners to improve the success, shorten the time,and reduce the cost of research and development.

Web: http://www.wuxiapptec.com .

About QIAGEN:

QIAGEN N.V., a Netherlands holding company, is the leading global providerof sample and assay technologies. Sample technologies are used to isolate andprocess DNA, RNA, and proteins from biological samples such as blood or tissue.Assay technologies are used to make such isolated bio-molecules visible.QIAGEN has developed and markets more than 500 sample and assay products aswell as automated solutions for such consumables. The company provides itsproducts to molecular diagnostics laboratories, academic researchers,pharmaceutical and biotechnology companies, and applied testing customers forpurposes such as forensics, animal or food testing, and pharmaceutical processcontrol. QIAGEN's assay technologies include one of the broadest panels ofmolecular diagnostic tests available worldwide. This panel includes thedigeneHPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer,as well as a broad suite of solutions for infectious disease testing andcompanion diagnostics. QIAGEN employs more than 3,400 people in over 30locations worldwide. Further information about QIAGEN can be found athttp://www.qiagen.com/.For further information, please contact: WuXi AppTec Inc. Ronald Aldridge Director of Investor Relations Tel: +1-201-585-2048 Email: Ron_Aldridge@wuxiapptec.com

SOURCE WuXi AppTec Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Sanofi-aventis Commences Tender Offer for All Outs...
S
deCODE Finds Genetic Factors Impacting Key Clinica...